DB16810InvestigationalGene Therapies
Domofenogene zalfaparvovec, formerly known as BMN-307, is an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy developed by BioMarin Pharmaceutical.
- Code names
- BMN-307
Resolves to
Compound
What you can answer from here — as of April 23, 2025
Which companies are running trials of Domofenogene zalfaparvovec, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account